Indegene acquires US-based Medical Marketing Economics for $10-M

Bangalore-based Indegene has acquired US-based Medical Marketing Economics (MME) for $10 million. MME is a pricing, reimbursement and market access services provider with experience in rare diseases, oncology, orphan drugs, biosimilars and newer technologies like gene therapy and CAR-T (Chimeric Antigen Receptor T-cell therapy). Indegene raised $200 million from investment firms Carlyle and Brighton Park Capital in February and is looking at more acquisitions in the regulatory, safety, patient-side space.